Sign in or create an account to add this stock to your watchlist.
-logo.jpg "Veru logo")
Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Industry, Sector and Symbol
Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897
Debt
Debt-to-Equity Ratio0.14
Current Ratio1.53
Quick Ratio1.19
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.66 million
Price / Sales8.97
Cash FlowN/A
Price / CashN/A
Book Value$0.91 per share
Price / Book2.52
Profitability
EPS (Most Recent Fiscal Year)($0.25)
Net Income$-6,610,000.00
Net Margins-87.78%
Return on Equity-21.72%
Return on Assets-16.38%
Miscellaneous
Employees175
Outstanding Shares53,510,000
Veru (NASDAQ:VERU) Frequently Asked Questions
What is Veru's stock symbol?
Veru trades on the NASDAQ under the ticker symbol "VERU."
How were Veru's earnings last quarter?
Veru Inc (NASDAQ:VERU) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $2.57 million for the quarter, compared to analysts' expectations of $7.60 million. Veru had a negative net margin of 87.78% and a negative return on equity of 21.72%. View Veru's Earnings History.
When is Veru's next earnings date?
What price target have analysts set for VERU?
2 equities research analysts have issued twelve-month target prices for Veru's shares. Their forecasts range from $5.00 to $5.00. On average, they expect Veru's share price to reach $5.00 in the next year. View Analyst Ratings for Veru.
Who are some of Veru's key competitors?
Some companies that are related to Veru include Supreme Cannabis (FIRE), Medical Facilities (DR), ArQule (ARQL), Zealand Pharma Aktieselskabet (ZLDPF), Computer Programs & Systems (CPSI), Starpharma (SPL), Merus (MRUS), Concert Pharmaceuticals (CNCE), Virtus Health (VRT), Scholar Rock (SRRK), Weed (BUDZ), Mersana Therapeutics (MRSN), Antares Pharma (ATRS), Depomed (DEPO) and Sinovac Biotech (SVA).
Who are Veru's key executives?
Veru's management team includes the folowing people:
- Mr. O. B. Parrish, Co-Founder & Vice Chairman (Age 85)
- Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 59)
- Dr. Harry Fisch, Chief Corp. Officer & Director (Age 59)
- Dr. Mitchell S. Steiner, Pres, CEO & Director (Age 57)
- Mr. Kevin J. Gilbert, Sr. VP of Corp. Devel. & Legal and Sec.
Has Veru been receiving favorable news coverage?
Headlines about VERU stock have been trending somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Veru earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the company an impact score of 46.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Veru?
Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veru's stock price today?
One share of VERU stock can currently be purchased for approximately $2.29.
How big of a company is Veru?
Veru has a market capitalization of $122.54 million and generates $13.66 million in revenue each year. The company earns $-6,610,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Veru employs 175 workers across the globe.
How can I contact Veru?
Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]
MarketBeat Community Rating for Veru (VERU)
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.
Veru (NASDAQ:VERU) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Veru in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 118.34%. The high price target for VERU is $5.00 and the low price target for VERU is $5.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $5.00 | $5.00 | $5.00 |
| Price Target Upside: | 118.34% upside | 182.49% upside | 249.65% upside | 254.61% upside |
Veru (NASDAQ:VERU) Consensus Price Target History
Veru (NASDAQ:VERU) Analyst Ratings History
Show:
(Data available from 6/17/2016 forward)
Veru (NASDAQ:VERU) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 3/25/2014 | quarterly | $0.07 | 3.84% | 4/28/2014 | 4/30/2014 | 5/7/2014 |
| 3/24/2014 | quarterly | $0.07 | | | 4/30/2014 | 4/7/2014 |
| 12/16/2013 | quarterly | $0.07 | 3.56% | 1/27/2014 | 1/29/2014 | 2/5/2014 |
| 10/4/2013 | quarterly | $0.07 | 2.87% | 10/28/2013 | 10/30/2013 | 11/6/2013 |
| 7/16/2013 | quarterly | $0.07 | 2.99% | 7/29/2013 | 7/31/2013 | 8/7/2013 |
| 3/27/2013 | quarterly | $0.07 | 3.87% | 4/29/2013 | 5/1/2013 | 5/8/2013 |
| 1/3/2013 | quarterly | $0.06 | 3.25% | 1/28/2013 | 1/30/2013 | 2/6/2013 |
(Data available from 1/1/2013 forward)
Veru (NASDAQ VERU) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 37.00%
Institutional Ownership Percentage: 4.80%
Veru (NASDAQ VERU) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2018 | Harry Fisch | Director | Buy | 5,000 | $1.96 | $9,800.00 | |  |
| 3/16/2018 | Mitchell Shuster Steiner | Insider | Buy | 20,000 | $1.96 | $39,200.00 | | |
| 3/14/2018 | Harry Fisch | Director | Buy | 10,000 | $1.87 | $18,700.00 | | |
| 3/12/2018 | Harry Fisch | Director | Buy | 10,000 | $1.80 | $18,000.00 | | |
| 3/9/2018 | Harry Fisch | Director | Buy | 10,000 | $1.88 | $18,800.00 | | |
| 3/8/2018 | Mitchell Shuster Steiner | Insider | Buy | 20,000 | $1.88 | $37,600.00 | | |
| 3/7/2018 | Harry Fisch | Director | Buy | 24,000 | $1.62 | $38,880.00 | | |
| 3/6/2018 | Mitchell Shuster Steiner | Insider | Buy | 20,000 | $1.50 | $30,000.00 | | |
| 9/15/2017 | Mitchell Shuster Steiner | Insider | Buy | 100,000 | $1.63 | $163,000.00 | 7,764,767 | |
| 9/13/2017 | Harry Fisch | Director | Buy | 34,250 | $1.51 | $51,717.50 | | |
| 8/30/2017 | Mitchell Shuster Steiner | Insider | Buy | 5,625 | $1.66 | $9,337.50 | | |
| 8/23/2017 | Jesus Socorro | Director | Buy | 7,100 | $1.44 | $10,224.00 | 7,100 | |
| 6/12/2017 | Mitchell Shuster Steiner | Insider | Buy | 55,000 | $1.27 | $69,850.00 | 645,502 | |
| 6/9/2017 | Elgar Peerschke | Director | Buy | 50,000 | $1.25 | $62,500.00 | 145,520 | |
| 6/8/2017 | Elgar Peerschke | Director | Buy | 4,967 | $1.15 | $5,712.05 | 93,605 | |
| 6/7/2017 | Daniel Haines | CFO | Buy | 6,000 | $1.14 | $6,840.00 | 83,931 | |
| 6/6/2017 | Elgar Peerschke | Director | Buy | 2,852 | $1.15 | $3,279.80 | 90,553 | |
| 6/1/2017 | Daniel Haines | CFO | Buy | 10,000 | $1.10 | $11,000.00 | 77,931 | |
| 5/30/2017 | Harry Fisch | Director | Buy | 12,000 | $1.27 | $15,240.00 | | |
| 5/24/2017 | Harry Fisch | Director | Buy | 10,000 | $1.10 | $11,000.00 | | |
| 5/22/2017 | Harry Fisch | Director | Buy | 24,750 | $1.02 | $25,245.00 | | |
| 5/17/2017 | Daniel Haines | CFO | Buy | 5,000 | $1.01 | $5,050.00 | 67,931 | |
| 5/15/2017 | Daniel Haines | CFO | Buy | 5,000 | $1.03 | $5,150.00 | 62,931 | |
| 5/15/2017 | O B Parrish | Director | Buy | 20,000 | $1.02 | $20,400.00 | 834,849 | |
| 5/12/2017 | David R Bethune | Director | Buy | 20,000 | $1.03 | $20,600.00 | 415,982 | |
| 5/11/2017 | Lucy Lu | Director | Buy | 5,000 | $1.00 | $5,000.00 | 5,000 | |
| 3/20/2017 | Georges Makhoul | Director | Buy | 100,000 | $1.05 | $105,000.00 | 189,444 | |
| 2/24/2017 | Daniel Haines | CFO | Buy | 7,931 | $1.03 | $8,168.93 | 54,000 | |
| 12/15/2016 | David R Bethune | Director | Buy | 200 | $1.06 | $212.00 | 405,982 | |
| 8/16/2016 | Andrew S Love Jr | Director | Buy | 20,214 | $1.39 | $28,097.46 | 114,626 | |
| 8/15/2016 | Andrew S Love Jr | Director | Buy | 4,786 | $1.32 | $6,317.52 | 93,712 | |
| 6/10/2016 | Andrew S Love Jr | Director | Buy | 15,000 | $1.36 | $20,400.00 | 81,136 | |
| 6/6/2016 | Andrew S Love Jr | Director | Buy | 1,210 | $1.40 | $1,694.00 | 66,136 | |
| 5/24/2016 | Michele Greco | CFO | Buy | 4,000 | $1.28 | $5,120.00 | 67,845 | |
| 5/24/2016 | O B Parrish | CEO | Buy | 10,000 | $1.29 | $12,900.00 | 814,849 | |
| 5/23/2016 | William R Gargiulo Jr | Director | Buy | 500 | $1.26 | $630.00 | 102,500 | |
| 5/20/2016 | David R Bethune | Director | Buy | 100 | $1.26 | $126.00 | 249,115 | |
| 12/18/2015 | O B Parrish | CEO | Buy | 10,000 | $1.48 | $14,800.00 | 846,849 | |
| 12/15/2015 | Andrew S. Love, Jr. | Director | Buy | 25,000 | $1.47 | $36,750.00 | 39,926 | |
| 2/5/2015 | Karen Louise King | CEO | Buy | 1,000 | $3.86 | $3,860.00 | | |
| 8/12/2014 | O B Parrish | Director | Buy | 5,000 | $4.05 | $20,250.00 | | |
| 8/6/2014 | Donna Felch | Director | Buy | 2,500 | $3.90 | $9,750.00 | | |
| 8/4/2014 | Karen Louise King | CEO | Buy | 2,000 | $3.94 | $7,880.00 | | |
| 5/13/2014 | Stephen M Dearholt | Director | Sell | 203,936 | $6.05 | $1,233,812.80 | | |
| 3/18/2014 | William R Gargiulo Jr | Director | Buy | 1,000 | $6.81 | $6,810.00 | | |
| 3/17/2014 | O B Parrish | Director | Buy | 5,000 | $6.74 | $33,700.00 | | |
| 12/20/2013 | Stephen M Dearholt | Director | Buy | 2,000 | $8.27 | $16,540.00 | | |
| 12/18/2013 | David R Bethune | Director | Buy | 4,000 | $8.07 | $32,280.00 | | |
| 3/8/2013 | Michele Greco | CFO | Buy | 1,000 | $7.01 | $7,010.00 | | |
| 9/17/2012 | Stephen M Dearholt | Director | Sell | 25,000 | $7.02 | $175,500.00 | | |
| 8/9/2012 | Michael Pope | VP | Sell | 17,056 | $5.90 | $100,630.40 | | |
| 8/8/2012 | Richard E Wenninger | Director | Sell | 3,260 | $6.00 | $19,560.00 | | |
(Data available from 1/1/2013 forward)
Veru (NASDAQ VERU) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th
finance.yahoo.com - May 30 at 5:34 PM |
 | Opinion: Finally, a simple solution to confusing health-care prices
www.marketwatch.com - May 23 at 8:01 AM |
 | Banned pregnancy drug tied to ADHD generations later
www.reuters.com - May 23 at 8:01 AM |
 | A Guide to Gynecological Exams: What Should — and Shouldn't — Happen
www.nytimes.com - May 20 at 5:42 PM |
| Denise Morrison Quits as Campbell Chief, Further Cutting Female CEO Ranks
www.nytimes.com - May 20 at 5:42 PM |
 | USC tried to protect its reputation more than its female students. How'd that work out?
www.latimes.com - May 20 at 5:42 PM |
 | Female Health (VERU) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - May 18 at 3:53 PM |
| Veru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 5:30 PM |
| Veru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 8:25 AM |
| Female Health (VERU) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:55 PM |
 | Mother's Day Gifts For Active Women
www.forbes.com - May 11 at 9:05 AM |
| Female Health (VERU) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 10 at 7:51 PM |
| Female Health (VERU) Releases Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 10 at 6:33 PM |
 | Veru's (VERU) CEO Mitchell Steiner on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:34 PM |
| Veru Reports Fiscal 2018 Second-Quarter Financial Results
finance.yahoo.com - May 9 at 8:23 AM |
| Female Health (VERU) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 7 at 9:16 AM |
| When Doctors Downplay Women's Health Concerns
www.nytimes.com - May 5 at 8:23 AM |
| Head to Head Comparison: West Pharmaceutical Services (WST) & Female Health (VERU)
www.americanbankingnews.com - May 5 at 1:20 AM |
| Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 American Urological Association Meeting
finance.yahoo.com - May 3 at 5:31 PM |
| Veru to Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call on May 9th
finance.yahoo.com - May 3 at 5:31 PM |
| Financial Survey: Female Health (VERU) vs. West Pharmaceutical Services (WST)
www.americanbankingnews.com - May 2 at 11:21 PM |
| The Best Bespoke Mother's Day Gifts From Female-Owned Brands
www.forbes.com - April 30 at 5:31 PM |
 | Women need to take an active role in their financial lives
www.cnbc.com - April 30 at 9:33 AM |
| Reviewing Female Health (VERU) and West Pharmaceutical Services (WST)
www.americanbankingnews.com - April 29 at 5:30 AM |
| Track's New Gender Rules Could Exclude Some Female Athletes
www.nytimes.com - April 26 at 5:27 PM |
 | Why the romaine lettuce E. coli outbreak affects more women than men
abcnews.go.com - April 26 at 5:27 PM |
| Head to Head Contrast: West Pharmaceutical Services (WST) and Female Health (VERU)
www.americanbankingnews.com - April 26 at 3:14 PM |
| The Menopause-Alzheimer's Connection
www.nytimes.com - April 20 at 5:36 PM |
| Gender equality in the sciences is improving, but more work is needed
abcnews.go.com - April 20 at 5:36 PM |
| Female Health (VERU) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:52 AM |
| Head-To-Head Analysis: Female Health (VERU) and OMNOVA Solutions (OMN)
www.americanbankingnews.com - April 18 at 9:17 PM |
 | NYC Removes Statue Honoring 19th Century Surgeon Who Experimented On Female Slaves
www.huffingtonpost.com - April 18 at 8:37 AM |
| Female Health (VERU) Earns Buy Rating from Analysts at Rodman & Renshaw
www.americanbankingnews.com - April 15 at 10:00 PM |
| Female Health (VERU) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 9 at 5:52 PM |
| Comparing Female Health (VERU) and OMNOVA Solutions (OMN)
www.americanbankingnews.com - April 9 at 9:19 AM |
| OMNOVA Solutions (OMN) vs. Veru (VERU) Head to Head Contrast
www.americanbankingnews.com - April 5 at 3:08 AM |
| Veru (VERU) Downgraded by ValuEngine
www.americanbankingnews.com - April 3 at 10:58 PM |
| Carlisle Companies (CSL) versus Veru (VERU) Head-To-Head Survey
www.americanbankingnews.com - April 1 at 5:15 PM |
| Veru (VERU) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - March 30 at 11:40 PM |
| Veru (VERU) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 30 at 1:04 PM |
 | Form 3 VERU INC. For: Mar 20 Filed by: Getzenberg Robert
www.streetinsider.com - March 28 at 8:00 AM |
| Form 3 VERU INC. For: Mar 20 Filed by: Rankowitz Michael L
www.streetinsider.com - March 24 at 5:33 PM |
| Form 4 VERU INC. For: Mar 20 Filed by: Rankowitz Michael L - StreetInsider.com
www.streetinsider.com - March 23 at 8:10 AM |
| Form 3 VERU INC. For: Mar 20 Filed by: Rankowitz Michael L - StreetInsider.com
www.streetinsider.com - March 23 at 8:10 AM |
| Veru, Inc. (VERU) Says FDA Granted Fee Waiver for Tamsulosin ... - StreetInsider.com
www.streetinsider.com - March 23 at 8:10 AM |
| Veru, Inc. (VERU) Says FDA Granted Fee Waiver for Tamsulosin DRS New Drug Application
www.streetinsider.com - March 22 at 5:45 PM |
| FDA Grants Fee Waiver for Tamsulosin DRS New Drug Application
finance.yahoo.com - March 22 at 5:45 PM |
 | ZEAL Displays Vigor, MDWD Getting Healed, VERU Up 80% YTD - Nasdaq
www.nasdaq.com - March 21 at 8:00 AM |
| Veru, Inc. (VERU) Announces VERU-111 Effective Against Prostate Cancer in Preclinical Study - StreetInsider.com
www.streetinsider.com - March 17 at 5:40 PM |
| Pre-Open Movers 03/16: (SEED) (DXR) (VERU) Higher; (OSTK) (TIF) (W) Lower (more...) - StreetInsider.com
www.streetinsider.com - March 17 at 5:40 PM |
Veru (NASDAQ:VERU) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Veru (NASDAQ:VERU) Income Statement, Balance Sheet and Cash Flow Statement
Veru (NASDAQ VERU) Stock Chart for Sunday, June, 17, 2018
Loading chart…
